# Rituximab to Treat Severe Hemophilia A

> **NCT00331006** · PHASE2 · COMPLETED · sponsor: **Carelon Research** · enrollment: 23 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00331006
- **Lead sponsor:** Carelon Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2010-11
- **Final completion:** 2012-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2013-06-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331006, "Rituximab to Treat Severe Hemophilia A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00331006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*